Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.58 SEK | -2.36% | +0.87% | +76.26% |
May. 16 | Diamyd Medical AB Updates on the Registrational Phase 3 Trial | CI |
Apr. 18 | Diamyd Medical Raises SEK57 Million in Rights Issue | MT |
Sales 2024 * | 3M 285K | Sales 2025 * | 3M 285K | Capitalization | 1.15B 110M |
---|---|---|---|---|---|
Net income 2024 * | -133M -12.64M | Net income 2025 * | -165M -15.68M | EV / Sales 2024 * | 339 x |
Net cash position 2024 * | 139M 13.21M | Net cash position 2025 * | 30M 2.85M | EV / Sales 2025 * | 375 x |
P/E ratio 2024 * |
-8.71
x | P/E ratio 2025 * |
-7.02
x | Employees | 26 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 63.2% |
Latest transcript on Diamyd Medical AB
1 day | -2.36% | ||
1 week | +0.87% | ||
1 month | +8.43% | ||
3 months | -17.52% | ||
6 months | +66.62% | ||
Current year | +76.26% |
Managers | Title | Age | Since |
---|---|---|---|
Ulf Hannelius
CEO | Chief Executive Officer | 49 | 16-04-09 |
Founder | 83 | 95-12-31 | |
Anna Styrud
DFI | Director of Finance/CFO | 63 | 09-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 83 | 95-12-31 | |
Director/Board Member | 63 | 11-12-31 | |
Director/Board Member | 52 | 21-04-27 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 11.58 | -2.36% | 147,946 |
24-05-30 | 11.86 | +4.96% | 163,458 |
24-05-29 | 11.3 | -2.42% | 207,412 |
24-05-28 | 11.58 | -0.34% | 318,190 |
24-05-27 | 11.62 | +1.22% | 128,679 |
Delayed Quote Nasdaq Stockholm, May 31, 2024 at 11:29 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+76.26% | 110M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- DMYD B Stock